GlassScriptPhysician profile
Robert R Heavner
NPI 1427051390
$5,060.89
in general payments reported to CMS, 2019-2025
27 companies · $995 in 2025
The $995 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2022: $651 · 2023: $1,784 · 2024: $1,516 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.21 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,452.87 | 2022-2025 | |
| Novo Nordisk INC | $622.55 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $563.72 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $516.06 | 2023-2025 | |
| Lilly USA, LLC | $259.81 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Corcept Therapeutics | $225.85 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $191.25 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $160.43 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $157.55 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $156.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.39 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $101.93 | 2022-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $101.07 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $70.97 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.56 | 2023-2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.35 | 2022-2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $34.02 | 2023-2024 | Quviviq |
| Dexcom, INC. | $33.67 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $33.47 | 2022-2023 | Steglujan, Steglatro, Belsomra |
| Sumitomo Pharma America, INC. | $32.40 | 2023-2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.99 | 2025 | Caplyta |
| Aimmune Therapeutics, INC. | $22.64 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.17 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $16.79 | 2025 | Voquezna |
| Allergan, INC. | $14.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Heavner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.